Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Terbinafine
Drug ID BADD_D02160
Description Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal.[L9065,L9068] It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues.[A1279] Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell wall synthesis pathway.[A1279,A1281,L9068] Terbinafine hydrochloride was granted FDA approval on 30 December 1992.[L9064]
Indications and Usage Terbinafine hydrochloride is indicated to treat fungal skin and nail infections caused by _Trichophyton_ species, _Microsporum canis_, _Epidermophyton floccosum_,[L9068] and _Tinea_ species.[L9065] Terbinafine hydrochloride also treats yeast infections of the skin caused by _Candida_ species and _Malassezia furfur_.[L9068]
Marketing Status approved; investigational; vet_approved
ATC Code D01AE15; D01BA02
DrugBank ID DB00857
KEGG ID D02375
MeSH ID D000077291
PubChem ID 1549008
TTD Drug ID D01AYJ
NDC Product Code 71205-152; 71335-1668; 69097-859; 62135-572; 63187-213; 76282-209; 72189-243; 59349-0008; 70518-1191
UNII G7RIW8S0XP
Synonyms Terbinafine | Terbinafine, (Z)-isomer | Terbinafine, (Z)- | Lamisil | (E)-N-(6,6-Dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride | TDT-067 | TDT 067 | TDT067 | DA 5505 | SF 86-327 | SF 86 327 | SF 86327 | SF-86-327 | SF86327 | Terbinafine Hydrochloride
Chemical Information
Molecular Formula C21H25N
CAS Registry Number 91161-71-6
SMILES CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Visual impairment06.02.10.0130.000879%Not Available
Vitreous opacities06.09.01.0070.000372%Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Withdrawal syndrome19.07.06.023; 08.06.02.012--Not Available
Yellow skin08.01.03.046; 23.03.03.042; 09.01.01.0090.000149%Not Available
Tubulointerstitial nephritis20.05.02.0020.000149%Not Available
Multiple sclerosis relapse17.16.01.0030.000298%Not Available
Acute generalised exanthematous pustulosis11.07.01.018; 10.01.01.034; 23.03.10.002; 12.03.01.0050.003798%Not Available
Hypoacusis04.02.01.0060.000402%
Onychoclasis23.02.05.0050.000506%Not Available
Application site vesicles23.03.01.009; 12.07.01.009; 08.02.01.0090.000223%Not Available
Paradoxical drug reaction08.06.01.0140.000298%Not Available
Peripheral swelling08.01.03.053; 02.05.04.0150.001996%Not Available
Gingival blister07.09.13.0010.000149%Not Available
Lip blister23.03.01.016; 07.05.01.0070.000149%Not Available
General physical health deterioration08.01.03.0180.000968%Not Available
Balance disorder17.02.02.007; 08.01.03.081--Not Available
Idiosyncratic drug reaction08.06.01.002--Not Available
Lupus-like syndrome23.03.02.004; 15.06.02.004; 10.04.03.0030.000670%Not Available
Deep vein thrombosis24.01.02.0030.000596%Not Available
Bile duct stenosis09.02.02.0010.000149%
Ear discomfort04.03.01.005--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.0010.000223%Not Available
Skin swelling23.03.03.0390.000298%Not Available
Type IV hypersensitivity reaction10.01.03.0220.000149%Not Available
Vanishing bile duct syndrome09.02.03.0030.000149%Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.000700%Not Available
Cutaneous lupus erythematosus10.04.03.007; 23.03.02.008; 15.06.02.0070.000968%Not Available
The 10th Page    First    Pre   10 11 12    Next   Last    Total 12 Pages